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The association of female genital schistosomiasis with the cervicovaginal microbiota and sexually 
transmitted infections is not well-described. We report weak evidence of an association between 
Trichomonas vaginalis and FGS, with a stronger association in women with higher burden FGS 
infection. 
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The cervicovaginal microbiota, including sexually transmitted infections (STI), have not been well-
described in female genital schistosomiasis (FGS). 
Methods 
Women (aged 18-31, sexually active, non-pregnant) were invited to participate at the final follow-up 
of HPTN 071 (PopART) Population Cohort in January-August 2018. We measured key species of the 
cervicovaginal microbiota (Lactobacillus crispatus, L. iners, Gardnerella vaginalis, Atopobium vaginae 
and Candida) and STI (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and 
Mycoplasma genitalium) using quantitative PCR (qPCR). We evaluated associations of microbiota 
and STI presence and concentration with FGS (qPCR-detected Schistosoma DNA in any of three 
genital specimens).  
Results 
The presence and concentration of key cervicovaginal species did not differ between participants 
with (n=30) or without FGS (n=158). A higher proportion of participants with FGS had T. vaginalis 
compared to FGS negative women (p=0.08), with further analysis showing that T. vaginalis was more 
prevalent among women with ≥2 Schistosoma qPCR positive genital specimens (50.0%, 8/16) than 
among FGS negative women (21.5% 34/158, p=0.01).  
Conclusions 
We found weak evidence of an association between T. vaginalis presence and FGS, with a stronger 
association in women with a higher burden FGS infection. Additional research is needed on potential 
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Female genital schistosomiasis (FGS) is caused when eggs from the waterborne parasite S. 
haematobium are entrapped in genital tissue [1]. FGS is prevalent in sub-Saharan Africa and is 
associated with adverse reproductive outcomes, including ectopic pregnancy, infertility, and 
prevalent HIV-1 [1, 2]. The cervicovaginal environment has been described as “optimal” when it is 
dominated by lactic-acid producing lactobacilli, commensal microorganisms that adhere to an intact 
vaginal squamous epithelium [3, 4], protecting against pathogens by acidifying the vagina and 
producing antimicrobial substances such as bacteriocins [3]. Bacterial vaginosis (BV) and 
vulvovaginal candidiasis are examples of “non-optimal” microbiota. BV is prevalent in women in sub-
Saharan Africa [5, 6] and is characterized by a shift from lactobacilli dominance to an increase in 
anaerobic species or yeast [4]. BV has important sexual and reproductive health consequences, 
including increased risk of pelvic inflammatory disease [5]. Additionally, BV has been associated with 
adverse pregnancy outcomes such as pre-term delivery [5, 7], a leading cause of under-five mortality 
in sub-Saharan Africa [8]. BV is also strongly associated with HIV-1 acquisition and other sexually 
transmitted pathogens infecting the genital tract, [5, 9, 10]. Studies employing 16S rRNA sequencing 
to evaluate the cervicovaginal microbiota suggest that high-intensity urinary S. haematobium 
infection, in the absence of investigation for genital involvement, may alter cervicovaginal 
microbiota diversity [11]. However, the relationship between cervicovaginal microbiota and FGS is 
not well characterized. 
 
Prevalent sexually transmitted infections (STIs) have been reported in women with [12] or in 
populations endemic for [13, 14] urinary schistosomiasis. However, evaluation of genital 
involvement (FGS) in studies of urinary S. haematobium and STI co-infection is not universally 
performed or reported [12-14]. The biopsy prevalence of FGS in participants with urinary S. 
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involvement (FGS) in urinary S. haematobium infection tenuous. A reference standard diagnostic 
does not exist for FGS. Thus, an FGS evaluation is often based on a combination of diagnostic tests 
including circulating anodic antigen (CAA), urine microscopy, colposcopy, tissue-based diagnostics 
(biopsy, Papanicolaou smear, wet prep), and polymerase chain reaction (PCR) [17-19]. Where an FGS 
evaluation has been performed, studies reporting PCR-defined FGS have either not investigated or 
reported STI prevalence [20-22] or STI prevalence has been correlated with visual FGS findings [23]. 
In this cross-sectional study we utilized PCR to detect Schistosoma DNA in the female genital tract 
and evaluated the association of PCR-defined FGS with the concentration and presence of key 
markers of the cervicovaginal microbiota, including STI. 
 
Methods 
Study setting and participants 
The cross-sectional bilharzia and HIV (BILHIV) study [18] was nested in HPTN 071 (PopART), a cluster 
randomized trial to measure the impact of an HIV-1 combination prevention package [24]. In HPTN 
071 (PopART), HIV-1 incidence was measured in a Population Cohort at baseline, 12, 24, and 36 
months [24]. Between January and August 2018, after the 36-month HPTN 071 (PopART) visit, 
community workers made home visits to women expressing interest in the BILHIV study [18]. Eligible 
women were aged 18-31 years, not pregnant, sexually active, and resident in one of two urban 
communities that participated in HPTN 071 (PopART) in Livingstone, Zambia. 
 
Home and clinic-based sample collection  
The home visit included written informed consent, a questionnaire, genital self-sampling (cervical 
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currently menstruating were invited to attend Livingstone Central Hospital cervical cancer clinic, 
where midwives performed cervicovaginal lavage (CVL). After speculum insertion, a bulb syringe was 
used to flush normal saline (10 mL) across the cervix and vaginal walls for one minute. CVL fluid was 
collected from the posterior fornices (S1-Text). CVL, vaginal and cervical swab specimens were used 
for quantitative PCR (qPCR) detection of Schistosoma; cervical swabs were used for characterization 
of the microbiota and STI by qPCR; urine was used for detection of circulating anodic antigen (CAA) 
and S. haematobium eggs by microscopy. 
 
Cervicovaginal images were captured with a portable colposcope (MobileODT, Tel Aviv, Israel) and 
were evaluated (EFK) for any of the four recognized FGS cervicovaginal manifestations: grainy sandy 
patches, homogenous yellow sandy patches, rubbery papules, and abnormal blood vessels [25]. 
Women with at least one of these manifestations [25] or with any positive urine or genital 
Schistosoma diagnostic were treated free of charge with 40 mg/kg praziquantel. Testing for STI was 
not performed at the point-of-care and participants with suspected STI were offered syndromic 
management, as per local guidelines [26].  
 
HIV-1 
Laboratory-based fourth-generation HIV-1 testing (Abbott Architect HIV Ag/Ab Combo Assay) was 
performed for HPTN 071 (PopART) Population Cohort participants at each study visit [24].  
 
Urine microscopy and Circulating Anodic Antigen 
Urine was centrifuged and examined by microscopy for S. haematobium eggs. The participant was 
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utilizing up-converting reporter particles for the quantification of CAA was performed on urine 
samples, as previously described [18, 27]. Analyzing the equivalent of 417 L urine (wet reagent, 
UCAAhT417), a test result indicating a CAA value >0.6 pg/mL was considered positive [28]. 
 
qPCR for detection of Schistosoma DNA 
Detection of the Schistosoma-specific internal-transcribed-spacer-2 (ITS2) target by qPCR was 
performed at LUMC, as previously described (S1-Text) [18, 29]. DNA extraction of 200 µL of CVL, 
cervical or vaginal swab fluid was done with QIAamp spin columns (QIAGEN Benelux; Venlo, The 
Netherlands) according to manufacturer’s guidelines. The qPCR output was reported in cycle 
threshold values (Ct-values) and parasite DNA loads were categorized by the following pre-specified 
values: high (Ct<30), moderate (30≤Ct <35), low (35≤Ct<50) and negative (no amplification) [30].  
 
Cervicovaginal microbiota characterization and STI detection 
We quantified Lactobacillus crispatus as a key marker of vaginal health. Additionally, we 
characterized markers of a “non optimal” cervicovaginal microbiota (Gardnerella vaginalis and 
Atopobium vaginae), as well as L. iners (an enigmatic and highly prevalent lactobacillus), C. albicans 
and STI (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas 
vaginalis). STI were quantified by qPCR using the S-DiaCTNGTM (for C. trachomatis and N. gonorrhea) 
and S-DiaMGTVTM kits (for M. genitalium and T. vaginalis) (Diagenode Diagnostics, Seraing, Belgium) 
on DNA from cervical swabs at Ghent University (Ghent, Belgium) according to the manufacturer’s 
instructions. Quantification of A. vaginae, G. vaginalis, L. crispatus, L. iners and Candida species was 
performed in the Laboratory Bacteriology Research, Ghent using the LightCycler480® and Software 
Version 1.5 (Roche, Basel, Switzerland) (S1-Text). The concentration of each species was expressed 
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In this study we employed various diagnostic tests to evaluate urinary schistosome infection (CAA 
and urine microscopy), and FGS (portable colposcopy and Schistosoma DNA on CVL and genital 
swabs). As previously described [32], participants were grouped by diagnostic test results into three 
mutually exclusive categories: FGS, at least one positive Schistosoma qPCR on a genital specimen 
(cervical swab, vaginal swab and/or CVL); FGS negative, negative results on all diagnostic methods; 
probable FGS, genital Schistosoma qPCRs negative but urinary schistosomiasis positive (as defined 
above), in combination with one of four clinical findings suggestive of FGS on any colposcope-
obtained photograph [25].  
 
Patient consent statement 
The study was approved by the University of Zambia Biomedical Research Ethics Committee (011-08-
17), the Zambia National Health Research Authority and the London School of Hygiene and Tropical 
Medicine Ethics Committee (14506). Permission to conduct the study was given by Livingstone 
District Health Office and the Livingstone Central Hospital superintendent. Participants provided 
written informed consent. 
 
Statistical Methods 
All participants with FGS (n=30) and all participants with probable FGS (n=25) were selected for 
characterization of the cervicovaginal microbiota and STI by qPCR on cervical swabs. Three FGS 
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number generator. The FGS negative participants were frequency matched by age to participants 
with FGS (age groups 18-19, 20-21, 22-23, 24-25, 26-27, 28-29, 30-31).  
 
Participant characteristics were summarized by median and interquartile range (IQR) for 
continuous variables, and by frequency and percentage for categorical variables. Differences 
in characteristics between FGS categories were evaluated using Fisher’s exact or chi-squared 
tests. For cervicovaginal microbiota and STI species with at least 20% of sample results 
detectable by qPCR (i.e. ≥20% prevalence), p-values for comparison of presence, median 
(IQR), and log10 concentration mean between FGS and FGS negative groups were calculated 
from chi-squared test, ranksum test, and t-test, respectively. For species with <20% 
prevalence, species presence was compared between FGS groups using Fisher’s exact test. To 
enable investigation of potential confounding, concentrations of cervicovaginal microbiota 
with ≥20% prevalence were log-transformed to normalize their distribution, and linear 
regression used to evaluate the association between FGS and mean log concentration of each 
organism (ge/mL) in univariable and multivariable analysis. We developed a causal 
framework (S1-Figure) to inform our minimal adjustment set, and adjusted for age, education 
and community of residence. For all species, logistic regression was used to calculate crude 
and adjusted odds ratio (OR) for presence versus absence by FGS group; due to the relatively 
low number of participants with detectable concentrations, logistic regression analyses only 
adjusted for age. Given the exploratory nature of this work, we did not correct for multiple 
comparisons. 
Our primary analysis focused on the detection of Schistosoma DNA in the genital tract (FGS 
versus FGS negative). A secondary analysis compared FGS and probable FGS groups with 
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changes in presence and concentration of cervicovaginal key species, two ad-hoc analyses 
were performed: (1) participants with ≥2 genital samples with detectable Schistosoma DNA 
were compared with the FGS negative group, (2) participants with a moderate/high genital 
Schistosoma DNA concentration (Ct <35 in at least one of three samples) were compared 
with the FGS negative group. Data were analyzed using STATA 15.1 (Stata Corporation, 
College Station, TX).  
Results 
A total of 603 eligible women were enrolled in the BILHIV study and 213 (35.3%) were included in 
the present study (S2-Figure). Of those included, 14.1% (30/213) had FGS, defined by a positive 
genital Schistosoma qPCR from any of the following sites: 9.4% (20/213) cervical swab, 7.0% 
(15/213) vaginal swab, and 6.6% (14/211) CVL. In participants with FGS, portable colposcopy 
revealed sandy patches in 20% (6/30), abnormal blood vessels in 20% (6/30), and no clinical signs of 
FGS in 50% (15/30). Two women with FGS did not present to clinic for portable colposcopy and one 
had uninterpretable images. Of participants with FGS, 53.3% (16/30) had Schistosoma qPCR 
detected from multiple sites and 53.3% (16/30) had moderate/high genital Schistosoma DNA loads, 
these groups overlapped by 12 participants. Twenty-five women had probable FGS, and 74.2% 
(158/262) of the women who were negative on all diagnostic tests were randomly selected for 
inclusion in this study. Consistent with the FGS definitions, portable colposcopy in 100.0% (25/25) of 
the participants with probable FGS showed FGS-associated cervicovaginal manifestations. In the 
majority of participants with probable FGS, portable colposcopy showed sandy patches (76.0%, 
19/25), with 24% (6/25) of participants having abnormal blood vessels.  
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The majority of the participants were married/cohabitating, had received some secondary 
education, and were using hormonal contraception (Table-1). At the conclusion of HPTN 071 
(PopART), HIV-1 prevalence was 17.4% (37/213) among the women included in this study and one-
third had at least one STI (Table 1). Urinary schistosome infection, defined as either a positive urine 
microscopy (11.7%, 25/213) and/or positive CAA (20.7%, 44/213), was reported in 21.6% (46/213) of 
participants. There were differences between the three categories of FGS status for age (p=0.002), 
marital status (p=0.04), education (p=0.06), and employment (p=0.04) with participants in the 
probable FGS group more likely to be older, employed, and married than FGS and FGS negative 
participants. There was strong evidence of a difference in community of residence by FGS status 
(p<0.001) with participants with FGS and probable FGS more likely to live in Community A than 
participants in the FGS negative group (Table-1). Other characteristics were similar by FGS status. 
 
Primary comparison: FGS vs FGS negative 
Concentrations of evaluated species are shown in Figure-1. Compared to FGS negative women, there 
was no evidence of a difference in the presence or concentration of cervicovaginal L. crispatus, L. 
iners, A. vaginae, G. vaginalis or C. albicans in participants with FGS (Table-2). A higher proportion of 
participants with FGS had T. vaginalis present, although there was not strong evidence of an 
association (OR 2.11, 95% CI: 0.92 – 4.86, p=0.08, S1-Table). This result was similar after adjusting for 
age (S1-Table). Otherwise, compared to FGS negative women, the presence and concentration of 
other STI was similar in women with FGS (Table-2).  
 
Combining FGS and probable FGS groups, participants with FGS/probable FGS similarly had a higher 
prevalence of T. vaginalis compared to FGS negative participants (S2-Table, p=0.05). Otherwise, 
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and the presence of STI was similar in women with FGS/probable FGS compared to FGS negative 
participants (S2-Table). 
 
Ad-hoc Analysis – Schistosoma DNA concentration  
In participants (n=16) with FGS and moderate/high genital Schistosoma DNA concentration 
(Schistosoma qPCR Ct<35) the presence of T. vaginalis was higher than among the FGS negative 
participants (p=0.01, Table-3). Women with FGS and a moderate/high Schistosoma DNA 
concentration (Ct<35) had a higher mean concentration of G. vaginalis compared to FGS negative 
women (p=0.03, Table-3).   
 
Ad-hoc analysis – clinical disease burden 
In an ad-hoc analysis, participants (n=16) with a higher FGS burden, defined as ≥2 Schistosoma qPCR 
positive genital specimens, had higher prevalence of T. vaginalis compared to FGS negative 
participants (p=0.01, Table-4). There was also evidence of a difference in the median concentration 
and the mean log-concentration of L. iners (both p=0.03) compared to FGS negative women, with 
lower levels among the higher FGS burden group (Table-4).  
 
Discussion  
In this study, we describe the association of FGS with the cervicovaginal microbiota, including 
lactobacilli, Candida spp., markers of a “non-optimal” cervicovaginal environment, and STI. We did 
not find evidence that the presence or concentration of key cervicovaginal species was associated 
with FGS. While FGS was not associated with C. trachomatis, M. genitalium, or N. gonorrhoeae, 
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adjusting for age. This association was also present when participants with FGS and probable FGS 
were combined and is strengthened in the ad-hoc analyses of participants with higher burden FGS.  
 
We performed two ad-hoc analyses. High-intensity S. haematobium infection, in the absence of 
evaluation for FGS, has been associated with higher cervicovaginal alpha diversity [11]. Thus, first we 
investigated whether Schistosoma DNA concentrations might be associated with the cervicovaginal 
microbiota in 16 participants with a higher FGS burden, indicated by moderate/high genital 
Schistosoma DNA concentrations. In this ad-hoc analysis, we found that the G. vaginalis log-
concentration mean was higher in women with a higher FGS burden. Participants underwent CVL 
when they were not menstruating, and we have previously described that 66.2% (139/210) of 
women in this cohort had detectable CVL hemoglobin. Iron sources, like hemoglobin, are often 
required for bacterial growth [33]. G. vaginalis is well adapted to harvest iron from the environment 
[34] and higher concentrations of G. vaginalis coincide with menses [33]. Cervical tissue in women 
with FGS is more vascularized than non-egg containing tissue and thus, the abnormal cervical vessels 
and contact bleeding seen in clinical FGS provides a plausible link to increased concentrations of G. 
vaginalis in high-burden FGS [35].  
 
In a second ad-hoc analysis, we examined participants with multiple qPCR-positive genital specimens 
as a potential proxy marker of high-burden FGS and found that reduced L. iners concentration 
(median and log mean) was associated with high-burden FGS. The cervicovaginal microbiota was 
characterized with 16S rRNA sequencing in Tanzanian women with S. haematobium infection (n=16). 
Although power was limited, women with high-intensity S. haematobium infection had reduced 
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difference (p=0.39) [11]. Further research is needed to evaluate the relationship between L. iners 
presence and concentration in FGS.  
 
In both ad-hoc analyses, we found that T. vaginalis presence was higher among the participants with 
a higher FGS burden. Our finding supports results from a small South African study (n=45) that 
reported an association between FGS (diagnosed by identification of sandy patches on colposcopy) 
and T. vaginalis presence in young women (ages 15-23) [36]. Acquisition of T. vaginalis and S. 
haematobium may share common risk factors, like age and socioeconomic status [18]. We have 
previously described higher FGS prevalence amongst younger age groups [18]. Epidemiologic data 
from Zambian adolescents, sex-workers and pregnant women (aged 13-45 years) describes a T. 
vaginalis prevalence between 24.6-33.2% [37], consistent with the prevalence in our population 
(24.9%). While S. haematobium is geographically restricted to Africa and the Middle East, it is 
associated with poverty [38] and is acquired through contact with cercariae infested fresh water [1]. 
T. vaginalis is primarily sexually transmitted, is prevalent worldwide, with the highest prevalence in 
women from low-income countries [39]. Both S. haematobium [40] and T. vaginalis infection [41, 42] 
have been reported as risk factors for HIV-1 acquisition, although these associations are not 
universally reported [43]. Additionally, T. vaginalis may influence HIV-1 transmission. Studies in 
women not uniformly receiving anti-retroviral therapy (ART) with T. vaginalis show a decline in 
genital HIV-1 shedding after metronidazole therapy [44-46]. However, this decline in cervical HIV-1 
shedding was not seen in a study of Kenyan women receiving ART [47]. The highest global T. 
vaginalis incidence rates have been reported in Africa [39]. Overlapping synergies between T. 
vaginalis and S. haematobium cervicovaginal pathogenesis may begin with, but are not limited to, 
disruption of the cervicovaginal epithelium [48]. Both parasites have been associated with 
characteristic cervicovaginal manifestations [17, 49], the “strawberry cervix” in T. vaginalis [49] and 
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cervicovaginal epithelium in T. vaginalis infection potentially represent one mechanism of HIV-1 
vulnerability in what is likely a multifactorial cascade, including modulating the cervicovaginal 
immune environment [50-52], disabling innate immunity [51], and disrupting the local microbiota 
[52]. To disentangle the association between S. haematobium, T. vaginalis and HIV-1, future studies 
using sensitive molecular methods for both parasites are needed. Additionally, macrophage 
polarization can be influenced by the local immune environment, schistosomes, and T. vaginalis [53, 
54]. We have previously shown that, compared to FGS negative women, high-burden FGS is 
associated with higher concentrations of cervicovaginal Th2 cytokines [32]. A mouse model of 
urogenital S. haematobium infection suggested that the Th2 immune environment may be 
associated with delayed pathogen clearance [55]. Thus, further research is needed regarding the 
interaction between the immune environment and macrophage phenotypes in FGS and their role in 
potentially influencing T. vaginalis persistence.  
 
Our study is the first to evaluate cervicovaginal microbiota and STI in FGS defined by qPCR. This is 
particularly relevant in a population of sexually active, non-pregnant women in the context of high 
HIV-1 prevalence. However, there are also some relevant limitations. FGS does not have an accepted 
diagnostic reference standard and the sensitivity of cervicovaginal PCR for the detection of 
Schistosoma DNA is imperfect. Thus, studies using Schistosoma DNA to detect FGS may be subject to 
misclassification bias. To maximize sensitivity, we used the results of three genital specimens. This 
decision was supported by previous work showing a sensitivity of 80.0% (61.4 – 92.3%) with a 
specificity of 100.0% (99.3 – 100.0%) when vaginal and cervical swab PCR were compared with any 
positive genital PCR (CVL, cervical swab or vaginal swab) as the reference standard [18]. The study 
was conducted in an urban location with relatively low S. haematobium prevalence, thus the 
numbers of FGS cases in the primary and ad-hoc analyses were small, limiting precision in the effect 
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that showed a consistent pattern of association across primary and ad-hoc analyses, rather than 
over-interpreting significance testing for any one species in isolation. Evidence for these associations 
in the ad-hoc analyses should be viewed as hypothesis generating. Additionally, the cross-sectional 
study design limited our ability to assess FGS duration or the long-term impact on the prevalence 
and concentrations of key species or STI. There were a number of behavioral and biological factors 
that were not measured in our study including tobacco use [56], viral STI (human papillomavirus and 
herpes simplex virus-2) [56] and intravaginal cleansing practices [57]. As these factors may be 
associated with the cervicovaginal microbiota, we cannot exclude residual or unmeasured 
confounding. Genital swabs were self-collected by participants, raising the potential for false 
negative genital swabs. In future work, β-globin PCR could be implemented as a positive control to 
confirm the presence of human DNA [18]. Lastly, we defined FGS by Schistosoma DNA detection on 
qPCR, however we cannot exclude that cervicovaginal qPCR detected S. haematobium eggs from a 
sexual partner’s semen [18]. 
 
In conclusion, we report weak evidence of an association between T. vaginalis presence and FGS, 
with a consistently stronger association in women with a higher burden FGS infection. Additional 
research is needed to understand the interactions between S. haematobium and T. vaginalis, 
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Age in years – 
Median(IQR) 
 23 (22 – 24) 27 (23 – 31) 22 (21 – 24) 0.002
‡ 
 
Marital status Single 72 (45.6) 4 (16.0) 13 (43.) 0.04 
 Married or Cohabitating 81 (51.3) 20 (80.0) 17 (56.7)  
 Divorced, or Separated 5 (3.2) 1 (4.0) 0 (0.0)  
Education (highest 
level) 
None or Any Primary 
School 
35 (22.2) 12 (48.0) 10 (33.3 (10) 0.06 
 Any Secondary School 1111 (70.3) 13 (52.0) 19 (63.3)  
 Trade, Degree or higher 12 (7.6) 0 (0.0) 1 (3.3)  
District Community A 66 (41.8) 20 (80.0) 22 (73.3) <0.01 
 Community B 92 (58.2) 5 (20.0) 8 (26.7)  
Household members 1-3 51 (32.3) 4 (16.0) 12 (40.0) 0.3 
 4-5 61 (38.6) 13 (52.0) 8 (26.7)  
 6+ 46 (29.1) 8 (32.0) 10 (33.3)  
Employment status Not Working 117 (74.1)  14 (56.0) 26 (86.7) 0.04 
 Working 41 (25.9)  11 (44.0) 4 (13.3)  
Sexual behavior characteristics       
Age at sexual debut 
(years) 
8-16 64 (40.5) 11 (44.0) 17 (56.7) 0.4 
 17-19 74 (46.8) 13 (52.0) 10 (33.3)  
 20-24 20 (12.7) 1 (4.0) 3 (10.0)  
Lifetime sexual 
partners 
1 57 (36.1) 8 (32.0) 5 (16.7) 0.3 
 2 36 (22.8) 6 (24.0) 9 (30.0)  
 3 23 (14.6) 6 (24.0) 8 (26.7)  





No 26 (16.6) 2 (8.0) 3 (10.0) 0.5 
 Yes 131 (83.4) 23 (92.0) 27 (90.0)  




No 120 (76.9) 16 (66.7) 22 (73.3) 0.6
‡‡
 
 Yes 36 (23.1) 8 (33.3) 8 (26.7)  
HIV-1 Status Not Detected 132 (83.5) 20 (80.0) 24 (80.0) 0.8 
 Detected 26 (16.5) 5 (20.0) 6 (20.0)  
Any STI
***
 Not Detected 106 (67.1) 14 (56.0) 18 (60.0) 0.5 
 Detected 52 (32.9) 11 (44.0) 12 (40.0)  
Contraceptive Use      
Condoms No 132 (83.5) 20 (80.0) 26 (86.7) 0.8 
 Yes 26 (16.5) 5 (20.0) 4 (13.3)  
OCP No 148 (93.7) 22 (88.0) 29 (96.7) 0.5 
 Yes 10 (6.3) 3 (12.0) 1 (3.3)  
Injectable No 82 (51.9) 13 (52.0) 15 (50.0) 1.0
‡‡
 
 Yes 76 (48.1) 12 (48.0) 15 (50.0)  
Implant No 144 (91.1) 23 (92.0) 28 (93.3) 1.0 
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No 58 (36.7) 8 (32.0) 10 (35.7) 0.9
‡‡
 
 Yes 100 (63.3) 17 (68.0) 18 (64.3)  
Schistosomiasis-related Factors     
Urine microscopy Not Detected 158 (100.0) 19 (76.0) 11 (36.7) <0.001 
 Detected 0 (0.0) 6 (24.0) 19 (63.3)  
Urine CAA Negative 158 (100.0) 0 (0.0) 11 (36.7) <0.001 
 Positive 0 (0.0) 25 (100.0) 19 (63.3)  
      
*Fisher’s exact p-value unless otherwise indicated 
‡ Kruskal Wallis p-value 
‡‡ Chi squared p-value 
**Any sexual activity in the last 6 months 
†Participants who responded with “no answer” (n=1) are not shown in the table  
†† Participants who responded with “no answer” (n=3) are not shown in the table  
*** Any STI defined as the presence of at least one of N. gonorrhoeae, C. trachomatis, M. genitalium 
or T. vaginalis 
˜Any hormonal contraception is defined as use of injectable agents, implants, or oral contraceptive 
pills 
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Table 2 Presence and concentration of vaginal Lactobacilli, other key microbiota, and sexually transmitted infection, overall and by female 
genital schistosomiasis status  
 
Organism n(%) and 
Concentration* 






      
L. crispatus Presence 69 (32.4) 49 (31.0) 13 (43.3) 0.19 
 Median (IQR) 8.7x106 (2.6x105 – 
4.2x108) 
1.1x107 (2.6x105 – 
7.0x108) 
7.5x105 (1.9x105 – 
2.7x107) 
0.20 
 Log concentration 
mean 
16.01 16.38 14.82 0.19 
L. iners Presence 156 (73.2) 113 (71.5) 24 (80.0) 0.34 
 Median (IQR) 2.7x108 (3.8x107 – 
1.5x109) 
2.8x108 (3.9x107 – 
1.6x109) 
1.7x108 (1.6x107 – 
1.0x109) 
0.39 
 Log concentration 
mean 
18.93 18.98 18.36 0.33 
G. vaginalis Presence 156 (73.2) 115 (72.8) 23 (76.7) 0.66 
 Median (IQR) 7.7x106 (8.3x105 – 
5.2x107) 
8.1x106 (7.7x105 – 
4.8x107) 
3.8x106 (6.8x105 – 
6.4x107) 
0.93 
 Log concentration 
mean 
15.85 15.74 15.91 0.79 
A. vaginae Presence 152 (71.4) 112 (70.9) 19 (63.3) 0.41 
 Median (IQR) 5.8x107 (8.2x106 – 
2.1x108) 
5.8x107 (8.7x106 – 
2.0x108) 
3.0x107 (1.06x106 – 
2.8x108) 
0.83 
 Log concentration 
mean 
17.31 17.33 17.06 0.66 
T. vaginalis Presence 53 (24.9) 34 (21.5) 11 (36.7) 0.08 
 Median (IQR) 4.2x104 (173.0 – 2.3x106) 1.7x105 (56.9 – 6.3x106) 1.0x104 (5030.0 – 4.5x105) 0.53 
 Log concentration 
mean 
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Vaginal Microbiota with prevalence <20%    
N. 
gonorrheae 
Presence 13 (6.1) 12 (7.6) 0.0 (0) 0.22 
C. 
trachomatis 
Presence 17 (8.0) 13 (8.2) 3 (10.0) 0.72 
M. 
genitalium 
Presence 8 (3.8) 7 (4.4) 0 (0.0) 0.60 
C. albicans Presence 12 (5.63) 8 (5.1) 2 (6.7) 0.66 
 
*concentrations are expressed in genome equivalents/mL; 
** For species with >20% prevalence, p-values for presence, median (IQR) and log concentration mean from chi-squared test, ranksum test and t-
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Table 3 – Ad-hoc analysis of the presence and concentration of vaginal Lactobacilli, other cervicovaginal microbiota, and sexually transmitted 
infection in participants with moderate to high concentration of Schistosoma DNA (Ct <35) compared to female genital schistosomiasis negative 
participants 
 
Organism n(%) and Concentration* FGS Negative 
(n=158) 
FGS with Ct<35 
(n=16) 
p-value** 
     
L. crispatus Presence 49 (31.0) 6 (37.5) 0.60 
 Median (IQR) 1.1x107 (2.6x105 – 7.0x108) 1.2x106 (3.0x105 – 2.0x107) 0.28 
 Log concentration mean 16.38 14.27 0.19 
L. iners Presence 113 (71.5) 11 (68.75) 0.82 
 Median (IQR) 2.8x108 (3.9x107 – 1.6x109) 7.5x107 (3.6x106 – 7.5x108) 0.30 
 Log concentration mean 18.98 17.86 0.21 
G. vaginalis Presence 115 (72.8) 13 (81.3) 0.46 
 Median (IQR) 8.1x106 (7.7x105 – 4.8x107) 1.5x107 (3.8x106 – 3.1x108) 0.11 
 Log concentration mean 15.74 17.45 0.03 
A. vaginae Presence 112 (70.9) 13 (81.3) 0.38 
 Median (IQR) 5.8x107 (8.7x106 – 2.0x108) 1.6x108 (1.6x107 – 2.8x108) 0.70 
 Log concentration mean 17.33 17.38 0.95 
T. vaginalis Presence 34 (21.5) 8 (50.0) 0.01 
 Median (IQR) 1.7x105 (56.9 – 6.3x106) 8085.0 (5210.0 – 1.0x106) 0.56 
 Log concentration mean 10.88 10.09 0.70 
Vaginal Microbiota with Prevalence <20%   
N. gonorrheae Presence 12 (7.6) 0 (0.0) 0.61 
C. trachomatis Presence 13 (8.2) 2 (12.5) 0.63 
M. genitalium Presence 7 (4.4) 0 (0.0) 1.0 
C. albicans Presence 8 (5.1) 2 (12.5) 0.23 
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** For species with >20% prevalence, p-values for presence, median (IQR) and log concentration mean from chi-squared test, ranksum test and t-
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Table 4 – Ad-hoc analysis of the presence and concentration of vaginal Lactobacilli, cervicovaginal microbiota, and sexually transmitted infection 
in participants with Schistosoma DNA detected in ≥ 2 genital specimens compared to female genital schistosomiasis negative participants 
 
Organism n(%) and Concentration* FGS Negative 
(n=158) 
≥ 2 PCR FGS 
(n=16) 
p-value** 
     
L. crispatus Presence 49 (31.0) 7 (43.8) 0.30 
 Median (IQR) 1.1x107 (2.6x105 – 7.0x108) 1.9x106 (7.7x104 – 2.7x107) 0.32 
 Log concentration mean 16.38 14.90 0.34 
L. iners Presence 113 (71.5) 10 (62.5) 0.45 
 Median (IQR) 2.8x108 (3.9x107 – 1.6x109) 5.1x107 (9.0x105 – 1.1x108) 0.03 
 Log concentration mean 18.98 17.00 0.03 
G. vaginalis Presence 115 (72.8) 14 (87.5) 0.20 
 Median (IQR) 8.1x106 (7.7x105 – 4.8x107) 1.6x107 (1.1x106 – 3.6x108) 0.29 
 Log concentration mean 15.74 16.85 0.16 
A. vaginae Presence 112 (70.9) 11 (68.8) 0.86 
 Median (IQR) 5.8x107 (8.7x106 – 2.0x108) 1.6x108 (2.7x107 – 3.2x108) 0.33 
 Log concentration mean 17.33 18.04 0.36 
T. vaginalis Presence 34 (21.5) 8 (50.0) 0.01 
 Median (IQR) 1.7x105 (56.9 – 6.3x106) 5680.0 (2967.5 – 1.0x106) 0.50 
 Log concentration mean 10.88 9.71 0.56 
Vaginal Microbiota with Prevalence <20%  
N. gonorrheae Presence 12 (7.6) 0 (0.0) 0.61 
C. trachomatis Presence 13 (8.2) 2 (12.5) 0.63 
M. genitalium Presence 7 (4.4) 0 (0.0) 1.0 
C. albicans Presence 8 (5.1) 1 (6.3) 0.59 
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** For species with >20% prevalence, p-values for presence, median (IQR) and log concentration mean from chi-squared test, ranksum test and t-
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